Status:
COMPLETED
Follow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy Studies
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Gene Transfer
Eligibility:
All Genders
Brief Summary
This study will provide follow-up evaluations of breast cancer or multiple myeloma patients who received gene therapy (gene transfer) as part of their participation in an NIH protocol. Gene therapy is...
Detailed Description
This Protocol aims to provide long-term follow-up of breast cancer and multiple myeloma subjects previously receiving autologous primitive marrow and blood hematopoietic cells exposed to gene transfer...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Subjects who received gene transfer products on the following protocols: MB 361, 96-C-0007, T-95-0096; MB 294, 92-C-0161, T-92-0018; MB 310, 93-C 0208, T-92-0192; or 92-H-0057, T-92-0139.
- EXCLUSION CRITERIA:
- Patients unwilling to participate.
Exclusion
Key Trial Info
Start Date :
March 6 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 20 2014
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00427726
Start Date
March 6 2003
End Date
May 20 2014
Last Update
December 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892